drugset / Trial / NCT02304289
Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma
Phase 1
Terminated
2 enrolled
University Hospital, Ghent
Anticancer Fund, Belgium · collabUniversity Ghent · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the Safety and Pharmacokinetics of Oral Artesunate in patients with advanced hepatocellular carcinoma (HCC)
Timeline
- Start
- 2014-11
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Artesunate | Small molecule | 200 mg | Oral |
| Subject | Artesunate | Small molecule | 300 mg | Oral |
| Subject | Artesunate | Small molecule | 400 mg | Oral |